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Diabetes mellitus (DM) is a widespread disease leading to 
the development of serious complications, disability and 
premature death. A mandatory factor in the pathogenesis of type 1 
diabetes is absolute insulin deficiency, leading to characteristic 
metabolic disorders. The fundamental treatment of Type 1 
diabetes costs a lot of millions dollars every year for the past 100 
years. Medicine spends a huge amount of money for daily insulin 
injections. Insulin therapy prevents death of patients from 
hyperglycemic coma, but doesn’t prevent the development of 
severe chronic complications. That is why, the search of more 
effective and preferably cardinal ways for antidiabetic treatment is 
extremely important. Great attention is paid to experiments on 
animals with experimental diabetes. 
The first model of diabetes was obtained in 1889 (Mering, 
Minkowski) as a result of removal of the pancreas in a dog. Later 
it was found that experimental diabetes can be obtained not only 
by pancreatectomy, but also after the introduction of various 
chemicals that destroy the insulin-producing β-cells of the 
pancreatic islets. Alloxan, streptozotocin (STC), dehydroascorbic 
acid or dithizone can be used. Each of which selectively causes β-
cell necrosis, preserving (unlike pancreatic ectomy) exocrine 
pancreatic function. Streptozotocin model of diabetes is the most 
popular. STC was first described in late 1950s as a promising 
antibiotic with antitumor activity, but it was used mainly as a 
diabetic drug due to its toxic side effect on pancreatic β-cells. In 
structure, it resembles sugar molecules, and this is enough to be 
captured and absorbed by cells using the glucose transporter 
GLUT2. The range of diabetic doses of STC is quite wide, 
ranging from 40 to 90 mg per 1 kg of body weight. A frequently 
used single intravenous dose in adult rats to induce IDDM of 
insulin-dependent diabetes is from 40 up to 60 mg / kg, but higher 
doses are also used. An intraperitoneal administration of a similar 
or higher dose is also effective, but a single dose below 40 mg / kg 
body weight may be ineffective. 
